See the DrugPatentWatch profile for Givosiran
What is givosiran used for?
Givosiran is a medicine used to treat acute hepatic porphyria (AHP). It works by reducing levels of the toxic substances that trigger attacks in people with AHP [1].
How does givosiran work?
Givosiran targets the liver enzyme pathway involved in producing heme. By interfering with upstream steps, it lowers production of porphyrin precursors that build up in AHP and can lead to acute attacks [1].
How is givosiran given?
Givosiran is administered as an injection [1].
Who should take givosiran (and who should not)?
The use of givosiran is tied to a confirmed diagnosis of acute hepatic porphyria. Specific eligibility and contraindications depend on the prescribing information and patient factors, which are typically detailed by the manufacturer and regulatory labeling [1].
What side effects are patients concerned about?
Commonly discussed side effects of givosiran include reactions related to treatment and potential liver and lab-related effects, since it targets processes in the liver. The full list depends on the specific approved product labeling [1].
How does givosiran compare with other AHP treatments?
In AHP, treatment strategies can include acute attack management during flares and preventive approaches. Givosiran is a preventive option that aims to reduce attack frequency by lowering disease-driving biochemical activity [1].
Where can I read the official prescribing details?
You can review official labeling and more complete safety/monitoring information through product-specific documents and drug references that summarize regulatory approval and clinical trial results [1].
Sources
- https://www.drugs.com/givosiran.html